Sign In
NewsRadar

Big VC rounds for Ganymed and MISSION to fight cancer

18 November 2013 17:47
By Tornado Staff

Today saw two big investments in life sciences companies that develop treatments for cancer.

The biggest investment was received by German biopharmaceutical company Ganymed Pharmaceuticals, which develops highly selective Ideal Monoclonal Antibodies (IMABs) for the treatment of cancer. The series E round totaled €45 million and was raised from existing investors ATS Beteiligungsverwaltung, MIG Fond, and FCPB Gany.

Ganymed will use the proceeds to accelerate the clinical development of its lead program IMAB362, including completion of the ongoing phase IIa and IIb clinical trials in gastroesophageal cancer and to prepare this first-in-class antibody for a phase III study. Also, the company will clinically validate its IVD test, CLAUDETECT18.2, as a predictive companion diagnostic test to IMAB362. Finally, the financing will help Ganymed to conduct a phase I/II clinical study of IMAB027 in ovarian cancer and develop a companion diagnostic test for this antibody.

Meanwhile, UK-based biotech company MISSION Therapeutics received a €23.8 million series B funding round from new investor Pfizer Venture Investments and existing backers Imperial Innovations Group, Sofinnova Partners, SR One and Roche Venture Fund. MISSION will use the current financing round to advance its lead programs for the treatment of various genetically defined cancers, through preclinical development and further development of its technology platform.

MISSION has progressed several small molecule discovery programs focused on key enzymes in the ubiquitin pathway to selectively target difficult-to-treat cancers. By targeting such ‘deubiquitylating’ enzymes (DUBs) which are involved in the DNA damage response, the company aims to induce synthetic lethality, a mechanism for the selective killing of tumor cells characterized by specific genetic abnormalities.



Related stories
Mucosis wins Wellcome Trust award and backing from current investors
Massive £50 million Series B round for UK-based Cell Medica
€6.3 million Series C for Humedics’ liver function diagnostic device
Medication safety system provider Mint Solutions secures €4.4 million
Catalan medical diagnostics company STAT-Diagnostica gets €17 million


Up
Data


23,670
Tech investments
From our Online Data Service
15,288
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Dec 15€1.3MBiotechnology
Dec 11€10.0MOther Biotechnology & Healthcare
Dec 11N/ABusiness applications
Dec 11N/AEnergy related
Dec 11€11.0MOther Biotechnology & Healthcare
Dec 11€4.3MBiopharmaceuticals
Dec 10€2.3MOther Software

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


Aug 17
Komed Health
komed health closes seed financing round

Jul 10
Komed Health
komed health to be supported by nokia and deutsche telekom

May 4
Vivet Therapeutics
vivet therapeutics raises €37.5 million in series a

Apr 5
Fliit
logistik-start-up fliit sammelt 1.5 millionen bei seed-finanzierung...

Jan 24
Spendesk
in addition to online payments, spendesk is now tackling travel exp...





About usContact usLegal Information
Copyright © 1999-2017
Emerging Technology Research Europe Inc. All rights reserved.